Director Laureen DeBuono retires from Rani Therapeutics board; committees reconstituted

Rani Therapeutics Holdings, Inc.

Laureen DeBuono resigned from Board effective April 24, 2025; no disagreement with company.
Board reconstituted Audit Committee: Rometty (Chair), Butel, Nanavaty; Compensation: Nanavaty (Chair), Ausiello.
Nominating and Governance Committee: Butel (Chair), Ausiello, Rometty.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Laureen DeBuono

Director

RANI · Rani Therapeutics Holdings, Inc.

Effective: 2025-04-24
Filed: April 30, 2025, 7:59 PM ET

On April 24, 2025, Laureen DeBuono notified the Board of Directors (“Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) that she has decided to retire from the Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Laureen DeBuono retired as Director at Rani Therapeutics Holdings, Inc..

Action: retired
Role: Director

Exact text from the filing

On April 24, 2025, Laureen DeBuono notified the Board of Directors (“Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) that she has decided to retire from the Board effective immediately.

View on SEC.gov

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-060586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.